38.61
前日終値:
$37.73
開ける:
$38.61
24時間の取引高:
757.75K
Relative Volume:
0.75
時価総額:
$3.73B
収益:
$225.27M
当期純損益:
$-140.06M
株価収益率:
-24.17
EPS:
-1.5974
ネットキャッシュフロー:
$-87.93M
1週間 パフォーマンス:
+3.10%
1か月 パフォーマンス:
+5.67%
6か月 パフォーマンス:
+12.66%
1年 パフォーマンス:
+57.98%
Ideaya Biosciences Inc Stock (IDYA) Company Profile
名前
Ideaya Biosciences Inc
セクター
電話
650-443-6209
住所
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare IDYA vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
IDYA
Ideaya Biosciences Inc
|
38.61 | 3.63B | 225.27M | -140.06M | -87.93M | -1.5974 |
|
VRTX
Vertex Pharmaceuticals Inc
|
516.34 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
789.45 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
|
MRNA
Moderna Inc
|
158.07 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
ARGX
Argen X Se Adr
|
995.77 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
196.94 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-11-24 | 開始されました | Truist | Buy |
| 2025-09-18 | 開始されました | Guggenheim | Buy |
| 2025-09-04 | 開始されました | Barclays | Overweight |
| 2025-09-04 | 開始されました | Citizens JMP | Mkt Outperform |
| 2025-07-22 | 開始されました | TD Cowen | Buy |
| 2025-07-10 | 再開されました | Goldman | Neutral |
| 2025-06-26 | 開始されました | Wells Fargo | Overweight |
| 2024-11-18 | 開始されました | Stephens | Overweight |
| 2024-11-05 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-10-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-07-08 | 開始されました | Mizuho | Outperform |
| 2024-03-08 | 開始されました | BTIG Research | Buy |
| 2023-08-08 | 開始されました | SVB Securities | Outperform |
| 2023-05-24 | 開始されました | Goldman | Buy |
| 2023-04-24 | アップグレード | Stifel | Hold → Buy |
| 2023-03-23 | 開始されました | Berenberg | Buy |
| 2023-02-28 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-12-28 | 開始されました | CapitalOne | Overweight |
| 2022-10-27 | 開始されました | Citigroup | Buy |
| 2022-08-15 | ダウングレード | Stifel | Buy → Hold |
| 2022-07-18 | 再開されました | Oppenheimer | Outperform |
| 2022-03-10 | アップグレード | Stifel | Hold → Buy |
| 2021-09-23 | 開始されました | Stifel | Hold |
| 2021-06-04 | 再開されました | Robert W. Baird | Outperform |
| 2021-03-11 | 開始されました | Guggenheim | Buy |
| 2020-10-07 | 開始されました | Wedbush | Outperform |
| 2020-09-01 | 開始されました | Northland Capital | Outperform |
| 2020-07-13 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-06-17 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-04-06 | 開始されました | H.C. Wainwright | Buy |
| 2020-03-13 | 開始されました | ROTH Capital | Buy |
| 2019-10-17 | 開始されました | Oppenheimer | Outperform |
| 2019-09-10 | 開始されました | Robert W. Baird | Outperform |
| 2019-06-17 | 開始されました | Citigroup | Buy |
| 2019-06-17 | 開始されました | JP Morgan | Neutral |
| 2019-06-17 | 開始されました | Jefferies | Buy |
すべてを表示
Ideaya Biosciences Inc (IDYA) 最新ニュース
IDEAYA at citigroup’s biopharma back to school summit 2026: pipeline breadth - Investing.com Canada
IDYA: NDA submission, ESMO data, and Roche collaborations set the stage for major oncology advances - TradingView
IDEAYA Biosciences at Cantor Fitzgerald conference: launch and pipeline push - Investing.com
IDEAYA Biosciences Doses First Patient in Phase 3 Trial - grafa.com
Guggenheim raises Ideaya Biosciences stock price target on DLL3 data - Investing.com
Guggenheim raises Ideaya Biosciences stock price target on DLL3 data By Investing.com - Investing.com Canada
IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma - PR Newswire
IDEAYA at wells fargo healthcare conference: darovasertib nears NDA By Investing.com - Investing.com Nigeria
Phase III path opens for Ideaya’s IDE-849 in DLL3 ADC horse race - BioWorld News
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Definium Therapeutics (DFTX) and IDEAYA Biosciences (IDYA) - theglobeandmail.com
Mizuho Securities Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Citizens upgrades Ideaya Biosciences stock rating on IDE849 progress By Investing.com - Investing.com Nigeria
IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences - 富途牛牛
Citizens upgrades Ideaya Biosciences stock rating on IDE849 progress - Investing.com
Avoiding Lag: Real-Time Signals in (IDYA) Movement - Stock Traders Daily
IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer - PR Newswire
IDEAYA Biosciences Announces Successful FDA Type C Meeting For IDE849 DLL3 TOP1 ADC On Phase 3 Registrational Trial Design For Potential Accelerated And Full Approval In Extensive Stage Small Cell Lung Cancer - marketscreener.com
IDEAYA Biosciences (IDYA) Slips 2.3% to $40.81 as Biotech Momentum FadesMomentum Factor - vinanet.vn
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Ideaya Biosciences stock hits 52-week high at 40.88 USD By Investing.com - Investing.com Nigeria
Ideaya Biosciences stock hits 52-week high at 40.88 USD - Investing.com
Ideaya Biosciences: Darovasertib De-Risks A Self-Reinforcing Oncology Platform (IDYA) - Seeking Alpha
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - Eastern Progress
IDEAYA (IDYA) Close: Adds 1.43% to Close at $39.67 at the Close; Technical Setup: the Near-Term Reference Band Stretches From $37.69 to $41.65 in the Available RecordFloat Adjusted Cap - vinanet.vn
Great Lakes Advisors LLC Makes New Investment in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA (IDYA) Results Check: The EPS Result Is Below Expectation in Latest Trading; Shares Close 2.48% Higher for the Current SessionEarnings Miss Alert - Vinanet
symbol__ Stock Quote Price and Forecast - CNN
IDEAYA partners with Genentech on pancreatic cancer trial By Investing.com - Investing.com South Africa
IDEAYA partners with Genentech on pancreatic cancer trial - Investing.com
IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer - PR Newswire
Bank of America Corp DE Has $31.39 Million Stake in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA Biosciences (IDYA) Cash Flow Statement - Moomoo
Walleye Capital LLC Buys Shares of 386,183 IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Baker Bros. Advisors (IDYA) reports 5.2% IDEAYA stake and capped warrants - Stock Titan
IDEAYA Biosciences (IDYA) Holds Near $37 as Bulls Eye Breakout Above $38.81 ResistanceVolume Breakout Ideas - Vinanet
J.P. Morgan Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $62 - Moomoo
IDEAYA Biosciences (IDYA) Short Interest & Short Float | Updated Aug 2026 - marketbeat.com
How (IDYA) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
IDEAYA Biosciences (NASDAQ:IDYA) Displays Perfect Technical Strength and Breakout Setup - ChartMill
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $58 - Moomoo
IDEAYA Biosciences Inc (IDYA) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
IDEAYA Biosciences (NASDAQ:IDYA) Is In A Strong Position To Grow Its Business - Moomoo
RBC Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $48 - Moomoo
The Bull Case For IDEAYA Biosciences (IDYA) Could Change Following Wider Loss And New Roche Partnership - Yahoo Finance
IDEAYA Biosciences (NASDAQ:IDYA) Given New $59.00 Price Target at Truist Financial - MarketBeat
Truist Financial Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $59 - Moomoo
A Quick Look at Today's Ratings for IDEAYA Biosciences(IDYA.US), With a Forecast Between $48 to $60 - Moomoo
IDEAYA BIOSCIENCES, INC. : LEERINK PARTNERS CUTS TARGET PRICE TO $31 FROM $37 - Bitget
IDEAYA Biosciences 2Q 2026: Revenue $8.86M, EPS $(1.22) — 10-Q Summary - TradingView
Ideaya Biosciences Inc (IDYA) 財務データ
収益
当期純利益
現金流量
EPS
Ideaya Biosciences Inc (IDYA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Ruiz Briseno Andres | Chief Accounting Officer |
Jul 07 '26 |
Sale |
40.01 |
9,550 |
382,131 |
26,466 |
大文字化:
|
ボリューム (24 時間):